GlassScriptPhysician profile
Lori A Deemer
NPI 1770585317
$1,825.92
in general payments reported to CMS, 2019-2025
28 companies · $17.95 in 2025
The $17.95 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $798 · 2020: $320 · 2021: $517 · 2022: $30.01 · 2023: $28.29 · 2024: $114 · 2025: $17.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $160.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $369.98 | 2019-2022 | |
| Novo Nordisk INC | $217.88 | 2019-2024 | Wegovy |
| Abbvie INC. | $166.91 | 2021-2023 | |
| Allergan, INC. | $117.84 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $117.65 | 2019-2021 | |
| Medtronic, INC. | $100.52 | 2024 | Signia |
| Astellas Pharma US INC | $99.95 | 2019 | |
| Glaxosmithkline, LLC. | $79.00 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.18 | 2019-2020 | |
| Pfizer INC. | $70.60 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $63.38 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $40.08 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $39.80 | 2021 | |
| Abbott Laboratories | $28.44 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $25.41 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $24.71 | 2019 | |
| Dexcom, INC. | $21.79 | 2021 | |
| Eisai INC. | $20.86 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.12 | 2019 | |
| Exact Sciences Corporation | $17.95 | 2025 | The Cologuard Plus Collection Kit |
| Ultragenyx Pharmaceutical INC. | $17.07 | 2021 | |
| Janssen Pharmaceuticals, INC | $15.74 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $14.96 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $14.30 | 2021 | |
| Amgen INC. | $12.85 | 2020 | |
| Sanofi Pasteur INC. | $12.74 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.64 | 2019 | |
| Circassia INC. | $11.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Deemer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.